keyword
MENU ▼
Read by QxMD icon Read
search

Prophylactic Cranial Irradiation

keyword
https://www.readbyqxmd.com/read/28073578/prophylactic-cranial-irradiation-after-definitive-chemoradiotherapy-for-limited-stage-small-cell-lung-cancer-do-all-patients-benefit
#1
Ahsan S Farooqi, Emma B Holliday, Pamela K Allen, Xiong Wei, James D Cox, Ritsuko Komaki
PURPOSE: Prophylactic cranial irradiation (PCI) can improve overall survival (OS) and suppress brain metastases (BM) in patients with limited-stage small cell lung cancer (LS-SCLC) after complete response to primary therapy. However, PCI can be toxic. We sought to identify characteristics of patients who may not benefit from PCI. METHODS: We identified 658 patients who received chemoradiotherapy at MD Anderson in 1986-2012; 364 received PCI and 294 did not. Median follow-up time was 21...
January 7, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28065620/treatment-response-and-prophylactic-cranial-irradiation-are-prognostic-factors-in-a-real-life-limited-disease-small-cell-lung-cancer-patient-cohort-comprehensively-staged-with-cranial-magnetic-resonance-imaging
#2
Chukwuka Eze, Olarn Roengvoraphoj, Maximilian Niyazi, Guido Hildebrandt, Rainer Fietkau, Claus Belka, Farkhad Manapov
INTRODUCTION: Prophylactic cranial irradiation (PCI) has proven to decrease the incidence of brain metastases (BMs), with a modest improvement in survival. PATIENTS AND METHODS: The impact of PCI was evaluated in 184 patients treated with chemoradiotherapy. PCI was applied to patients with disease with partial and complete response only when cranial magnetic resonance imaging before and after primary treatment revealed no BMs. Correlation between PCI and overall survival (OS), BM-free survival (BMFS), and time to progression (TTP) was analyzed to describe survival within subgroups...
November 21, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28027850/nine-year-experience-prophylactic-cranial-irradiation-in-extensive-disease-small-cell-lung%C3%A2-cancer
#3
Denise Bernhardt, Sebastian Adeberg, Farastuk Bozorgmehr, Nils Opfermann, Juliane Hoerner-Rieber, Michael C Repka, Jutta Kappes, Michael Thomas, Helge Bischoff, Felix Herth, Claus Peter Heußel, Jürgen Debus, Martin Steins, Stefan Rieken
BACKGROUND: In 2007, the European Organization for Research and Treatment of Cancer (EORTC) study (ClinicalTrials.gov identifier, NCT00016211) demonstrated a beneficial effect on overall survival (OS) with the use of prophylactic cranial irradiation (PCI) for extensive disease (ED) small-cell lung cancer (SCLC). Nevertheless, debate is ongoing regarding the role of PCI, because the patients in that trial did not undergo magnetic resonance imaging (MRI) of the brain before treatment. Also, a recent Japanese randomized trial showed a detrimental effect of PCI on OS in patients with negative pretreatment brain MRI findings...
December 2, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28011047/multi-institutional-experience-of-stereotactic-ablative-radiation-therapy-for-stage-i-small-cell-lung-cancer
#4
Vivek Verma, Charles B Simone, Pamela K Allen, Sameer R Gajjar, Chirag Shah, Weining Zhen, Matthew M Harkenrider, Christopher L Hallemeier, Salma K Jabbour, Chance L Matthiesen, Steve E Braunstein, Percy Lee, Thomas J Dilling, Bryan G Allen, Elizabeth M Nichols, Albert Attia, Jing Zeng, Tithi Biswas, Peter Paximadis, Fen Wang, Joshua M Walker, John M Stahl, Megan E Daly, Roy H Decker, Russell K Hales, Henning Willers, Gregory M M Videtic, Minesh P Mehta, Steven H Lin
PURPOSE: For inoperable stage I (T1-T2N0) small cell lung cancer (SCLC), national guidelines recommend chemotherapy with or without conventionally fractionated radiation therapy. The present multi-institutional cohort study investigated the role of stereotactic ablative radiation therapy (SABR) for this population. METHODS AND MATERIALS: The clinical and treatment characteristics, toxicities, outcomes, and patterns of failure were assessed in patients with histologically confirmed stage T1-T2N0M0 SCLC...
February 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27981260/once-daily-high-dose-radiation-%C3%A2-60-gy-treatment-in-limited-stage-small-cell-lung-cancer
#5
Amir Zahra, Tangel Chang, Taher Abu Hejleh, Muhammad Furqan, Gerald H Clamon, Sudershan K Bhatia, John M Watkins, Sarah L Mott, Logan L Ahmann, Kellie L Bodeker, Douglas R Spitz, John M Buatti, Bryan G Allen
BACKGROUND: To investigate outcomes and prognostic factors in patients treated with once daily high-dose (≥60 Gy) radiation therapy (HDRT) and concurrent platinum-based chemotherapy in limited stage small cell lung cancer (LS-SCLC). While we await current phase III trials to determine optimal radiation dose fractionation schemes in LS-SCLC, we report our experience in LS-SCLC with once daily HDRT. We hypothesized that HDRT would achieve similar efficacy and tolerability as twice daily therapy...
November 2016: J Oncol Transl Res
https://www.readbyqxmd.com/read/27978874/-concurrent-chemoradiotherapy-with-original-chemotherapy-regimens-may-not-be-suitable-for-patients-who-failed-to-respond-to-induction-chemotherapy%C3%A2-in-limited-stage-small-cell-lung-cancer
#6
Daquan Wang, Liming Xu, Lujun Zhao, Wencheng Zhang, Qingsong Pang, Ningbo Liu, Xi Chen, Xiuli Chen, Zhiyong Yuan, Ping Wang
BACKGROUND: The group of small cell lung cancer (SCLC) are usually highly sensitive to chemotherapy, and less than 15% of them are resistant to drugs. We respectively evaluate the correlation of the sequence and timing of radiotherapy with progression-free survival (PFS) and overall survival (OS) in patients with limited-stage SCLC (LS-SCLC), and to figure out whether concurrent chemoradiotherapy is superior to sequent chemoradiotherapy. METHODS: Sixty-seven patients diagnosed with LS-SCLC from January 2009 to June 2014 failed to respond to induction chemotherapy...
December 20, 2016: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/27969462/mini01-15-prophylactic-cranial-irradiation-pci-for%C3%A2-limited-small-cell-lung-cancer-lsclc-an-iaslc-physician-survey-topic-radiation-oncology
#7
Laurie E Gaspar, Françoise Mornex, Feng-Ming Spring Kong, Fred Hirsch
No abstract text is available yet for this article.
November 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27907849/association-between-dehydroepiandrosterone-sulfate-and-attention-in-long-term-survivors-of-childhood-acute-lymphoblastic-leukemia-treated-with-only-chemotherapy
#8
Yin Ting Cheung, Wassim Chemaitilly, Daniel A Mulrooney, Tara M Brinkman, Wei Liu, Pia Banerjee, Deokumar Srivastava, Ching-Hon Pui, Leslie L Robison, Melissa M Hudson, Kevin R Krull
Long-term survivors of childhood acute lymphoblastic leukemia (ALL) are at risk for neurocognitive impairment, as well as compromised hypothalamic-pituitary-adrenal (HPA) function. Dehydroepiandrosterone-sulfate (DHEAS) is an adrenal androgen commonly used as a marker of HPA function. In the general population, a low level of DHEAS has been associated with poorer cognition. At ≥2years post-treatment, we examined the association of DHEAS with attention outcomes in 35 male and 34 female long-term survivors of childhood ALL (mean[standard deviation] age at evaluation 14...
November 16, 2016: Psychoneuroendocrinology
https://www.readbyqxmd.com/read/27853828/prognostic-role-of-patient-gender-in-limited-disease-small-cell-lung-cancer-treated-with-chemoradiotherapy
#9
Olarn Roengvoraphoj, Chukwuka Eze, Maximilian Niyazi, Minglun Li, Guido Hildebrandt, Rainer Fietkau, Claus Belka, Farkhad Manapov
BACKGROUND: Previous studies have demonstrated that female gender could be a prognostic factor in limited-disease (LD) small-cell lung cancer (SCLC), but the correlation between patient gender and survival parameters remains unclear. PATIENTS AND METHODS: Data from 179 LD SCLC patients treated with definitive chemoradiotherapy (CRT) were reviewed. Influence of patient gender on time to progression (TTP), local control (LC), brain metastasis-free (BMFS), distant metastasis-free (DMFS) and overall survival (OS) was analysed...
November 16, 2016: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/27794411/outcome-in-patients-with-small-cell-lung-cancer-re-irradiated-for-brain-metastases-after-prior-prophylactic-cranial-irradiation
#10
Denise Bernhardt, Farastuk Bozorgmehr, Sebastian Adeberg, Nils Opfermann, Damian von Eiff, Juliane Rieber, Jutta Kappes, Robert Foerster, Laila König, Michael Thomas, Jürgen Debus, Martin Steins, Stefan Rieken
OBJECTIVES: Patients with brain metastases from small-cell lung cancer (SCLC) who underwent prior prophylactic cranial irradiation (PCI) are often treated with a second course of whole brain radiation therapy (Re-WBRT) or stereotactic radiosurgery (SRS) for purposes of palliation in symptomatic patients, hope for increased life expectancy or even as an alternative to untolerated steroids. Up to date there is only limited data available regarding the effect of this treatment. This study examines outcomes in patients in a single institution who underwent cerebral re-irradiation after prior PCI...
November 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27790279/the-younger-patients-have-more-better-prognosis-in-limited-disease-small-cell-lung-cancer
#11
Hye-Jin Kim, Chang-Min Choi, Seul-Gi Kim
BACKGROUND: Factors associated with the prognosis of patients with small cell lung cancer (SCLC) is relatively unknown, than of those with non-small cell lung cancer. This study was undertaken to identify the prognostic factors of SCLC. METHODS: The medical records of 333 patients diagnosed with SCLC at tertiary hospital from January 1, 2008, to December 31, 2012 were retrospectively reviewed. Patients were categorized by age (≤65 years vs. >65 years) and by extent of disease (limited disease [LD] vs extensive disease [ED])...
October 2016: Tuberculosis and Respiratory Diseases
https://www.readbyqxmd.com/read/27785518/analysis-of-risk-factors-for-pulmonary-complications-in-patients-with-limited-stage-small-cell-lung-cancer-a-single-centre-retrospective-study
#12
Beata Sas-Korczyńska, Elżbieta Łuczyńska, Wojciech Kamzol, Andrzej Sokołowski
INTRODUCTION: The most effective therapy in patients with limited-stage small cell lung cancer (LS SCLC) seems to be chemotherapy (using platinum-based regimens) and thoracic radiotherapy (TRT), which is followed by prophylactic cranial irradiation. MATERIALS AND METHODS: The analysed group comprised 217 patients who received combined treatment for LS SCLC, i.e. chemotherapy (according to cisplatin and etoposide schedule) and TRT (concurrent in 101 and sequential in 116 patients)...
October 26, 2016: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/27747011/treatment-outcomes-of-patients-with-small-cell-lung-cancer-without-prophylactic-cranial-irradiation
#13
Masakuni Sakaguchi, Toshiya Maebayashi, Takuya Aizawa, Naoya Ishibashi, Tsutomu Saito
BACKGROUND: Prophylactic cranial irradiation (PCI) is indicated for limited disease (LD) in small cell lung cancer (SCLC) patients who achieve a complete or near-complete response; however, it is sometimes not administered because of possible adverse reactions or patient refusal. Here we assessed treatment outcomes among patients with SCLC who were not treated with PCI. METHODS: The medical records of 60 patients (45 men, 15 women; mean age, 68 years; age range, 51-82 years) with SCLC were retrospectively reviewed...
September 2016: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/27732999/small-cell-lung-cancer
#14
Gregory P Kalemkerian
Small cell lung cancer (SCLC) is a high-grade neuroendocrine tumor characterized by rapid growth, early metastatic spread, and initial responsiveness to therapy. Although the incidence of SCLC is declining, it remains one of the common causes of cancer-related mortality. Initial evaluation of patients with SCLC should focus on determining the extent of disease and the ability of the patient to tolerate specific therapy. Positron emission tomography (PET) can improve the accuracy of staging and treatment planning in many patients...
October 2016: Seminars in Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/27725211/prophylactic-cranial-irradiation-for-patients-with-surgically-resected-small-cell-lung-cancer
#15
Jianlin Xu, Haitang Yang, Xiaolong Fu, Bo Jin, Yuqing Lou, Yanwei Zhang, Xueyan Zhang, Hua Zhong, Huimin Wang, Dan Wu, Baohui Han
INTRODUCTION: Data on prophylactic cranial irradiation (PCI) after complete resection of SCLC are limited. The purpose of this study was to investigate the impact of PCI in this population. METHODS: We retrospectively identified completely resected SCLC at the Shanghai Chest Hospital between January 2006 and January 2014. RESULTS: A total of 349 patients (115 patients who received PCI [the PCI-treated cohort] and 234 patients who did not [the non-PCI-treated cohort]) were included in the study...
October 7, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27717511/patient-preferences-regarding-prophylactic-cranial-irradiation-a-discrete-choice-experiment
#16
Margot Lehman, Peter Gorayski, Susanne Watson, Desiree Edeling, James Jackson, Jennifer Whitty
INTRODUCTION: In patients with non-small cell lung cancer (NSCLC) treated with chemoradiotherapy (CRT), prophylactic cranial irradiation (PCI) is not standard practice. This study determined patient preferences for PCI with respect to survival benefit, reduction in brain metastases (BM) and acceptable toxicity. METHODS: A Discrete Choice Experiment was completed pre- and post-treatment. Patients made 15 hypothetical choices between two alternative PCI treatments described by four attributes: amount of life gained, chance of BM, ability to care for oneself, and loss of memory...
November 2016: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/27703372/consolidation-chemotherapy-improves-progression-free-survival-in-stage-iii-small-cell-lung-cancer-following-concurrent-chemoradiotherapy-a-retrospective-study
#17
Xin-Ru Chen, Jian-Zhong Liang, Shu-Xiang Ma, Wen-Feng Fang, Ning-Ning Zhou, Hai Liao, De-Lan Li, Li-Kun Chen
BACKGROUND: Concurrent chemoradiotherapy (CCRT) is the standard treatment for limited-stage small-cell lung cancer (LD-SCLC). However, the efficacy of consolidation chemotherapy (CCT) in LD-SCLC remains controversial despite several studies that were performed in the early years of CCT use. The aim of this study was to reevaluate the effectiveness and toxicities associated with CCT. METHODS: This retrospective analysis evaluated 177 patients with stage IIIA and IIIB small-cell lung cancer (SCLC) who underwent CCRT from January 2001 to December 2013 at Sun Yat-Sen University Cancer Center (SYSUCC)...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27675962/a-prospective-study-of-hippocampal-sparing-prophylactic-cranial-irradiation-pci-in-limited-stage-small-cell-lung-cancer-sclc
#18
K J Redmond, R K Hales, X C Zhou, M Kummerlowe, H Sair, M Duhon, L R Kleinberg, G Rosner, T Vannorsdall
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27674652/current-patterns-of-care-for-patients-with-extensive-stage-small-cell-lung-cancer-survey-of-us-radiation-oncologists-on-their-recommendations-regarding-prophylactic-cranial-irradiation
#19
A Jain, J Luo, Y Chen, M A Henderson, C R Thomas, T Mitin
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27626317/risk-factors-of-brain-metastasis-during-the-course-of-egfr-tkis-therapy-for-patients-with-egfr-mutated-advanced-lung-adenocarcinoma
#20
Xiaoyan Ma, Hui Zhu, Hongbo Guo, Anqin Han, Haiyong Wang, Wang Jing, Yan Zhang, Li Kong, Jinming Yu
Controversial value of prophylactic cranial irradiation (PCI) in NSCLC in terms of survival benefit prompted us to explore the possible risk factors for brain metastasis (BM) during the course of EGFR-TKIs therapy from EGFR-mutated advanced lung adenocarcinoma and identify the potential population most likely to benefit from PCI, because BM remains a therapeutically challenging issue. We retrospectively reviewed the records of 134 patients with EGFR-mutated advanced lung adenocarcinoma between 2008 and 2012...
September 8, 2016: Oncotarget
keyword
keyword
13187
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"